Stem Cell Research Enhancement Act

Stem Cell Research Enhancement Act
Name	Stem Cell Research Enhancement Act
Enacted by	United States Congress
Introduced by	Tom Harkin
Enacted	2007 (attempt)
Status	Proposed legislation

Stem Cell Research Enhancement Act

The Stem Cell Research Enhancement Act was proposed United States federal legislation intended to expand federal support for biomedical investigations involving human embryonic stem cells. The measure intersected with controversies surrounding bioethics, patent law, and public health policy, engaging elected officials, scientific societies, advocacy groups, and judicial actors across multiple branches of the federal system.

Background and Legislative History

The bill emerged amid a broader policy contest that involved figures and institutions such as George W. Bush, Barack Obama, Tom Harkin, Arlen Specter, Nancy Pelosi, John Boehner, and organizations like the National Institutes of Health, American Medical Association, Howard Hughes Medical Institute, and National Academy of Sciences. Its development followed earlier disputes tied to executive actions by the Bush administration and subsequent administrative changes under the Obama administration. Important legislative moments connected to floor votes and committee actions occurred in bodies including the United States Senate, United States House of Representatives, Senate Judiciary Committee, and committees chaired by lawmakers from constituencies represented by institutions such as Harvard University, Stanford University, Johns Hopkins University, and Massachusetts Institute of Technology. The proposal was influenced by high-profile court proceedings before tribunals like the United States Court of Appeals for the District of Columbia Circuit and the United States District Court for the Northern District of California, and by precedents in rulings involving parties such as Sherley v. Sebelius and suits with plaintiffs linked to research universities and biotechnology firms including Geron Corporation, Advanced Cell Technology, and StemCells, Inc..

Provisions and Scope

The act sought to modify federal funding criteria administered by agencies including the Department of Health and Human Services and the National Institutes of Health to permit grants and contracts for research on human embryonic stem cell lines derived from excess embryos created by procedures at clinics such as Shady Grove Fertility Clinic and centers affiliated with medical centers like Massachusetts General Hospital and UCLA Health. It referenced standards similar to guidelines promulgated by panels convened by the National Academies of Sciences, Engineering, and Medicine and echoed consent frameworks developed at meetings linked to International Society for Stem Cell Research and advisory bodies such as the President's Council on Bioethics. The bill delineated eligibility and oversight mechanisms involving institutional review by offices comparable to Office for Human Research Protections, compliance with statutes including the Health Insurance Portability and Accountability Act for donor privacy, and specified interactions with patent regimes exemplified by decisions from the United States Patent and Trademark Office and cases like Association for Molecular Pathology v. Myriad Genetics.

Scientific and Medical Implications

Proponents argued that expanded funding would accelerate investigations relevant to translational therapies for conditions studied by entities such as American Heart Association, Juvenile Diabetes Research Foundation, Michael J. Fox Foundation for Parkinson's Research, and clinics specializing in Parkinson's disease, type 1 diabetes, spinal cord injury, and macular degeneration. Research communities at universities including University of California, San Francisco, Yale University, University of Pennsylvania, and laboratories supported by trusts like the Wellcome Trust anticipated advancements in pluripotency assays, differentiation protocols, disease modeling, and drug discovery. The act raised questions about interactions with technologies developed at institutions such as Salk Institute for Biological Studies, Cold Spring Harbor Laboratory, and companies like Regenocyte and iPS Biotech that worked on induced pluripotent stem cells, somatic cell nuclear transfer, and cell therapy manufacturing compliant with Food and Drug Administration requirements for investigational new drug applications and clinical trials overseen by institutional review boards and independent data safety monitoring boards.

Ethical, Legal, and Social Considerations

Ethical debate invoked positions articulated by ethicists associated with centers like Kennedy Institute of Ethics, philosophers and theologians linked to Georgetown University, Notre Dame, and Yale Divinity School, and advocacy groups such as Americans United for Life, Catholic Bishops Conference, Planned Parenthood, and March of Dimes. Issues included informed consent processes used by fertility clinics, property rights debates influenced by cases involving Eugenics Record Office-era controversies, and international comparisons with regulatory frameworks in jurisdictions represented by United Kingdom, Sweden, Japan, and Germany. Legal scholars at institutions like Columbia Law School and Harvard Law School examined constitutional questions touching on standing doctrine, separation of powers, and statutory interpretation under acts such as the Administrative Procedure Act and federal appropriations statutes.

Political Debate and Stakeholder Positions

Supporters included scientific societies like the American Association for the Advancement of Science, patient advocacy coalitions exemplified by the Alzheimer's Association, and biotech industry groups such as Biotechnology Innovation Organization. Opponents included religious organizations like the United States Conference of Catholic Bishops and political factions within the Republican Party and segments of the Democratic Party that cited moral concerns. Campaigns and lobbying efforts involved firms such as Akin Gump Strauss Hauer & Feld and advocacy networks affiliated with think tanks including the Heritage Foundation and Brookings Institution. Media coverage and editorial positions from outlets like The New York Times, The Washington Post, and The Wall Street Journal shaped public discourse alongside testimonies delivered in hearings by researchers from Cleveland Clinic and patient testimonies organized by groups tied to foundations such as the Michael J. Fox Foundation.

Implementation, Funding, and Oversight

Implementation mechanisms would have relied on appropriations via acts processed through the United States Congress appropriations committees and execution by agencies including the National Institutes of Health and Office of Management and Budget. Oversight provisions envisioned roles for inspectorates and watchdogs like the Government Accountability Office and ethics oversight analogous to the Office of Government Ethics, with reporting requirements to committees chaired by lawmakers from delegations including California's congressional delegation and Massachusetts congressional delegation. Funding pathways intersected with private philanthropy from organizations such as the Gates Foundation and collaborations involving research consortia at centers like the Broad Institute and the California Institute for Regenerative Medicine model, while compliance and audit procedures referenced standards used by National Science Foundation grant administration.

Category:United States proposed legislation